Max Narr

Overview

Max Narr is a Germany-based venture investor and healthcare entrepreneur. He is co-founder and general partner of Blue Forest Ventures, an early-stage deep-tech venture firm, and was previously managing director of the drug-development company Endosane Pharmaceuticals GmbH and chief investment officer of the Berlin-based Sanity Group, according to Startuprad.io interviews and a Sanity Group announcement.

Why this entity matters

Narr's career links two parts of the DACH ecosystem that often work separately: pharmaceutical and cannabinoid-based drug development on one side and early-stage deep-tech venture investing on the other. As a founder-operator turned investor, he is a useful reference for how scientific spin-outs are packaged into investable equity stories, a theme he discussed at length in a Startuprad.io episode. His move from a corporate-venture and joint-venture structure at Sanity Group to a deep-tech fund also illustrates how healthcare operators are entering the seed-stage investor community.

Career, company, or institutional background

A Sanity Group announcement dated 5 October 2021 https://sanitygroup.com/en/2021/10/05/sanity-group-joins-medicinal-cannabis-europe-as-executive-board-member%E2%80%8B/ describes Narr as managing director of Endosane Pharmaceuticals GmbH, responsible for business strategy and development, and as a qualified lawyer with a pharmaceutical and biotech background and earlier M&A and restructuring experience. The same announcement describes Endosane as a joint venture between Sanity Group and an international team of scientists led by Professor F. Markus Leweke and Dr. Cathrin Rohleder, developing medicines for neuropsychiatric disorders by targeting the endocannabinoid system.

In the Startuprad.io interview published in 2022, Narr is introduced as managing director of Endosane and as chief investment officer of Sanity Group, the Berlin-based company that develops products from cannabis components. By 2024 Startuprad.io introduced him as general partner of Blue Forest Ventures, and Crunchbase and TheOrg list him as co-founder and general partner of that firm https://theorg.com/org/blue-forest-ventures/org-chart/max-narr . In the 2024 episode, Narr described Blue Forest as investing in deep tech with ticket sizes of 500,000 to 1,000,000 euros, avoiding heavily regulated fields such as drug development, and using alternative data and AI to evaluate markets. An investor-database profile https://superscout.co/investor/blue-forest-ventures lists a Berlin base, a 2023 founding year and a wider range of 150,000 to 2 million euros; these third-party figures differ from the episode and were not reconciled for this record.

Role in the ecosystem

As a general partner at an early-stage fund and a former operating executive in biotech, Narr occupies a bridging role between scientific founders and capital providers in the German startup ecosystem. In the 2024 episode he described Blue Forest's approach as translating complex scientific ideas into compelling equity stories, supporting founders with commercial strategy and focusing on technology companies in Europe and beyond. These descriptions are his own and reflect the firm's positioning at the time of the interview, not verified investment performance.

Selected relationships and affiliations

Narr is publicly associated with Blue Forest Ventures as co-founder and general partner, with Endosane (catalogued as a separate Startuprad.io entity, endosane) as former managing director, and with Sanity Group (catalogued as sanity-group) as former chief investment officer. Endosane is a joint venture of Sanity Group and the research team around Professor Leweke and Dr. Rohleder. Sanity Group's founder Finn Hänsel is catalogued separately as finn-haensel and was a Startuprad.io guest. No other affiliations are asserted. Current roles at Endosane and Sanity Group were not confirmed in this research pass and are described only as former roles at the time of the cited sources.

Startuprad.io relevance

Startuprad.io interviewed Narr twice. A 2022 founder interview covered Endosane's joint-venture structure, its research origins and its openness to external investors with relevant contacts. A 2024 episode about Blue Forest Ventures covered the firm's deep-tech investment strategy, ticket sizes, regulatory exclusions and use of AI. Both posts were refreshed in September 2026, and the older interview was migrated from Startuprad.io's earlier Medium publication.

Public source context

This record draws on Startuprad.io's own interview posts, a Sanity Group press release, Crunchbase and TheOrg listings, an investor-database profile of Blue Forest Ventures and Narr's public LinkedIn profile as linked in Startuprad.io's show notes. Fund size, portfolio composition and current titles at Endosane and Sanity Group were not found in sufficiently reliable public sources and are omitted. Ticket sizes differ between the Startuprad.io episode and a third-party profile and are presented side by side without resolving the difference. Private-life information was not collected.

Startuprad.io coverage

Endosane Brings New Hope For Patients With Mental Health Conditions — Founder Interview
Published: 15 March 2026
Last updated: 20 September 2026
Coverage type: Interview
https://www.startuprad.io/post/endosane-brings-new-hope-for-patients-with-mental-health-conditions-founder-interview

Blue Forest Ventures: Transforming Scientific Research into Marketable Solutions
Published: 13 June 2024
Last updated: 20 September 2026
Coverage type: Interview
https://www.startuprad.io/post/blue-forest-ventures-transforming-scientific-research-into-marketable-solutions

About this record. This is the public Level 1 layer of Startuprad.io's entity intelligence architecture. Startuprad.io's deeper entity intelligence may include extended profiles, verified relationships, source trails, historical development, monitoring, news signals, custom entity sets, and analytical relationship mapping. These deeper layers are available through Startuprad.io's research, intelligence, and enterprise services.

Need deeper entity intelligence? Startuprad.io provides extended profiles, monitored entity sets, relationship analysis, source-backed research, and custom intelligence services for companies, investors, and institutions. → https://www.startuprad.io/become-a-partner

Interested in how scientific spin-outs become investable? Entrepreneurs Vault members get deeper operator-side analysis of deep-tech seed investors like Max Narr, including how founders can frame an equity story for early-stage funds.
▶ YouTube Membership: https://www.youtube.com/startupradio/join
✉️ Substack: https://startupradio.substack.com/subscribe

About Startuprad.io

Startuprad.io is a European B2B media, data and intelligence platform. It provides structured entity and ecosystem data, source-backed research, datasets and AI/training-data solutions, as well as strategic visibility and access to a professional European audience of founders, investors, executives and B2B decision-makers.

Organizations use Startuprad.io for intelligence and research, structured data and AI applications, executive and company positioning, and trusted B2B reach across Europe.

← All Startuprad.io entities: https://www.startuprad.io/entities

Canonical record: https://www.startuprad.io/entities/max-narr